Multiple myeloma vaccine - Aastrom Biosciences/Stanford University
Latest Information Update: 18 May 2006
At a glance
- Originator Aastrom Biosciences; Stanford University; Stanford University School of Medicine
- Developer Aastrom Biosciences; Stanford University
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 18 May 2006 Discontinued - Preclinical for Multiple myeloma in USA (unspecified route)
- 10 Oct 2002 Preclinical trials in Multiple myeloma in USA (unspecified route)